Press Releases
<< Back
Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China Healthcare Investment Partnering Symposium
Date:
Presentation Time:
Location: InterContinental Hangzhou -
Webcast:
http://wsw.com/webcast/brileyco20/eyes/
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative
implantable visual prosthetics to enable blind individuals to achieve
greater independence. Second Sight has developed, and now manufactures
and markets, the
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that
bypasses defunct retinal cells and stimulates remaining viable cells
inducing visual perception in individuals with severe to profound
retinitis pigmentosa (RP). The Argus II works by converting images
captured by a miniature video camera mounted on the patient's glasses
into a series of small electrical pulses, which are transmitted
wirelessly to an array of electrodes implanted on the surface of the
retina. These pulses stimulate the retina's remaining cells, intending
to result in the perception of patterns of light in the brain. The
patient must learn to interpret these visual patterns, having the
potential to regain some visual function. The Argus II was the first
artificial retina to receive widespread commercial approval, and is
offered at approved centers in
About the Orion Visual Cortical Prosthesis System
Like the Argus II, the Orion converts images captured by a miniature
video camera mounted on the patient's glasses into a series of small
electrical pulses. The Orion is designed to transmit these electrical
pulses wirelessly to an array of electrodes implanted on the surface of
the visual cortex, intended to result in the perception of patterns of
light. By bypassing the retina and optic nerve and directly stimulating
the visual cortex, a cortical prosthesis system has the potential to
restore useful vision to many more patients than the Argus II, including
patients completely blinded due to many reasons, including glaucoma,
diabetic retinopathy, or forms of cancer and trauma. The Company has
initiated a feasibility study in the U.S. at two centers: the
Safe Harbor
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange and Exchange Act of 1934, as
amended, which are intended to be covered by the "safe harbor" created
by those sections. All statements in this release that are not based on
historical fact are "forward looking statements." These statements may
be identified by words such as "estimates," "anticipates," "projects,"
"plans," or "planned," "seeks," "may," "will," "expects," "intends,"
"believes," "should," and similar expressions, or the negative versions
thereof, and which also may be identified by their context. All
statements that address operating performance or events or developments
that Second Sight expects or anticipates will occur in the future, such
as stated objectives or goals, or that are not otherwise historical
facts, are forward-looking statements. While management has based any
forward-looking statements included in this release on its current
expectations, the information on which such expectations were based may
change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially from
those in the forward-looking statements, as a result of various factors
including those risks and uncertainties described in the Risk Factors
and in Management's Discussion and Analysis of Financial Condition and
Results of Operations sections of our Annual Report, on Form 10-K, to be
filed on or before
Reconciliation to Non-GAAP Financial Measures
In addition to reporting all financial information required in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Non-GAAP net loss and Non-GAAP net loss per share which are non-GAAP financial measures. Non-GAAP net loss and Non-GAAP net loss per share are not measurements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Non-GAAP net loss and Non-GAAP net loss per share may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Non-GAAP net loss and Non-GAAP net loss per share, as defined by the Company, represent net loss adjusted for non-cash stock-based compensation and a reserve for excess inventory. Management believes that these non-GAAP financial measures provide useful supplemental information regarding the performance of the Company’s business operations and facilitates comparisons to the Company’s historical operating results. For a full reconciliation of Non-GAAP net loss to the most comparable GAAP financial measures, please see the tables at the end of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180308005842/en/
Source:
Investor Relations:
Institutional
Investors
In-Site Communications, Inc.
Lisa Wilson,
President
212-452-2793
lwilson@insitecony.com
or
Individual
Investors
MZ North America
Greg Falesnik, Managing
Director
949-385-6449
greg.falesnik@mzgroup.us
or
Media:
Nobles
Global Communications
Laura Nobles or Helen Shik
617-510-4373
Laura@noblesgc.com
Helen@noblesgc.com
